(Source: Immunomedics Inc) Microsoft Word - IMMUNOMEDICS REPORTS IMPROVED PFS RESULTS WITH IMMU-132 IN TNBC IMMUNOMEDICS,® INC. 300 The American Road, Morris Plains, New Jersey 07950 ¤ (973) 605-8200 ¤ Fax (973) 605-8282 IMMUNOMEDICS REPORTS IMPROVED PROGRESSION-FREE SURVIVAL RESULTS WITH SACITUZUMAB GOVITECAN IN TRIPLE- NEGATIVE BREAST CANCER -- Interim Median Progression-Free Survival (PFS) of 7.0 Months Reported at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics -- Boston, MA, November 9, 2015 --- Immunomedics, Inc. (Nasdaq: IMMU) today announced that patients with metastatic triple-negative breast cancer (TNBC) lived for a median of seven...
↧